Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Current and controversial issues in the neuroendocrine neoplasms treatment tactics
https://doi.org/10.33667/2078-5631-2024-27-28-32
Abstract
Neuroendocrine neoplasms (NENs) are a heterogeneous group of diseases that include well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). The increase in the incidence of NETs in recent decades, especially in Russia – from 0.05 to 5.19% per 100 thousand population from 2001 to 2019, determines a significant increase in interest among doctors and scientists in this problem. Existing domestic and foreign recommendations raise a number of controversial issues that require informed decisions in the course of new clinical trials.
About the Authors
V. A. Gorbunova
N.N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Gorbunova Vera A., DM Sci (habil.), professor, chief researcher
Moscow
E. V. Evdokimova
N.N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation
Russian Federation
Evdokimova Ekaterina V., oncologist at Dept of Drug Treatment (Chemotherapeutic) No. 1
Moscow
E. V. Artamonova
N.N. Blokhin National Medical Investigation Centre of Oncology; N.I. Pirogov Russian National Research Medical University; M. F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Artamonova Elena V., DM Sci (habil.), head of Dept of Drug Treatment (Chemotherapeutic) No. 1; professor at Dept of Oncology and Radiation Therapy; head of Dept of Oncology and Thoracic Surgery
Moscow
References
1. Sonbol MB, Mazza GL, Mi L, Oliver T, Starr J, Gudmundsdottir H, Cleary SP, Hobday T, Halfdanarson TR. Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Oncologist. 2022 Jul 5; 27 (7): 573–578. DOI: 10.1093/oncolo/oyac049. PMID: 35348774; PMCID: PMC9255979.
2. Gorbunova, Beltsevich, Alekseeva. Neuroendocrine tumors. General principles of diagnosis and treatment. Management. GEOTAR-Media, 2021. (In Russ.).
3. Dam G., Grønbæk H., Sundlöv A., Botling J., Sundin A., Petersen R.H., Langer S.W. Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. Acta Oncologica. 2023; 62 (5): 431–437. https://doi.org/10.1080/0284186X.2023.2212411
4. Baudin E., Caplin M., Garcia-Carbonero R., Fazio N., Ferolla P., Filosso P.L., Berruti A. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2021; 32 (4): 439–451. DOI: 10.1016/j.annonc.2021.01.003
5. National Comprehensive Cancer Network (2023). Neuroendocrine and Adrenal Tumors (version 1.2023).
6. Cavalcoli F, Gallo C, Coltro LA, Rausa E, Cantù P, Invernizzi P, Massironi S. Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It? Medicina (Kaunas). 2023 Oct 1; 59 (10): 1757. DOI: 10.3390/medicina59101757. PMID: 37893475; PMCID: PMC10608689.
7. Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T, Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study. Eur. J. Cancer. 2022 Nov; 175: 31–40. DOI: 10.1016/j.ejca.2022.07.033. Epub 2022 Sep 7. PMID: 36087395.
8. Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Müller HH, Arnold R; PROMID Study Group. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology. 2017; 104 (1): 26–32. DOI: 10.1159/000443612. Epub 2016 Jan 6. PMID: 26731483.
9. Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E, Thanh XT, Wolin EM, Ruszniewski P. CLARINET Investigators. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021 Feb; 71 (2): 502–513. DOI: 10.1007/s12020-020-02475-2. Epub 2020 Oct 14. PMID: 33052555; PMCID: PMC7881960.
10. WILLIAMS ED, SANDLER M. The classification of carcinoid tum ours. Lancet. 1963 Feb 2; 1 (7275): 238–9. DOI: 10.1016/s0140–6736(63)909516. PMID: 14000847.
11. Bachiri S, van Amstel P, Koppen IJN, van der Weide MC, Raphael MF, Gorter RR. Hemicolectomy versus appendectomy alone for appendiceal neuroendocrine tumours between 1–2 cm in size-are we overtreating? Transl Cancer Res. 2023 Sep 30; 12 (9): 2420–2424. DOI: 10.21037/tcr23–655. Epub 2023 Aug 17. PMID: 37859747; PMCID: PMC10583003.
12. Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix AI MIYOSHI, YUTAKA UEDA, TOMOKO KURITA, TADASHI KIMURA, KIYOSHI YOSHINO Anticancer Research Apr 2023, 43 (4) 13971405. DOI: 10.21873/anticanres.16288
13. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008 Jun 20; 26 (18): 3063–72. DOI: 10.1200/JCO.2007.15.4377. PMID: 18565894.
14. Andrini, E., Lamberti, G., Alberici, L. et al. An Update on Appendiceal Neuroendocrine Tumors. Curr. Treat. Options in Oncol. 2023; 24: 742–756. https://doi.org/10.1007/s11864-023-01093-0
15. Exarchou K., Stephens N.A., Moore A.R. et al. New Developments in Gastric Neuroendocrine Neoplasms. Curr Oncol. Rep. 2022; 24: 77–88. https://doi.org/10.1007/s11912–021–01175-y
Review
For citations:
Gorbunova V.A., Evdokimova E.V., Artamonova E.V. Current and controversial issues in the neuroendocrine neoplasms treatment tactics. Diagnostics and Oncotherapy (3). 2024;(27):28-32. (In Russ.) https://doi.org/10.33667/2078-5631-2024-27-28-32
Views:
157
Email this article 